Allergan (AGN) Receiving Somewhat Favorable Press Coverage, Study Shows
News articles about Allergan (NYSE:AGN) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Allergan earned a news impact score of 0.06 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.667166435454 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s rankings:
- European Commission Approves Mvasi For Treating Certain Types Of Cancer (pharmalive.com)
- Amgen/Allergan's Avastin Biosimilar Secures EU Approval (finance.yahoo.com)
- Amgen (AMGN) and Allergan’s (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by EC (streetinsider.com)
- Amgen And Allergan’s MVASI Gets EU Approval To Treat Certain Types Of Cancer (markets.businessinsider.com)
- Amgen (AMGN) and Allergan’s (AGN) MVASI For Treatment Of Certain Types Of Cancer Approved by EC – StreetInsider.com (streetinsider.com)
Allergan (NYSE AGN) traded up $1.69 during trading on Friday, reaching $181.33. 4,040,000 shares of the company traded hands, compared to its average volume of 2,840,000. Allergan has a 12-month low of $160.07 and a 12-month high of $256.80. The stock has a market cap of $59,750.00, a P/E ratio of -8.03, a price-to-earnings-growth ratio of 1.30 and a beta of 1.11. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.
Allergan announced that its board has initiated a stock buyback program on Monday, September 25th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its stock is undervalued.
A number of equities analysts have weighed in on the stock. Vetr lowered shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 price target on the stock. in a report on Wednesday, January 10th. Citigroup cut their target price on shares of Allergan to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 9th. ValuEngine downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Mizuho reissued a “buy” rating and issued a $267.00 target price on shares of Allergan in a research note on Monday, September 25th. Finally, Barclays reissued an “equal weight” rating on shares of Allergan in a research note on Monday, October 2nd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $226.95.
In other news, Director Christopher J. Coughlin purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 5th. The shares were purchased at an average price of $163.30 per share, with a total value of $1,633,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider William Meury sold 11,807 shares of Allergan stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Insiders have purchased a total of 17,630 shares of company stock worth $2,890,057 in the last ninety days. 0.36% of the stock is currently owned by insiders.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.